FDA clears 1st AI sepsis monitoring tool

Giles Bruce / beckershospitalreview - A tool from tech company Bayesian Health has become the first continuous AI sepsis monitor to gain FDA approval. The solution monitors hospital patients to detect deterioration and flag sepsis early on. The application was developed at Baltimore-based Joh…

AI Summary: Regulators have cleared the first AI‑driven sepsis early‑warning system for clinical deployment, enabling hospitals to use algorithmic alerts to identify patients at risk of deterioration earlier. The clearance opens the door for broader adoption of AI in acute care while renewing debates about clinical oversight, false alarms and integration into existing workflows.

#healthcare #publichealth #fda #digitalhealth #medicaldevices #hospitaloperations #infectiousdisease #healthit

As AI identifies more at-risk patients, health systems face a capacity challenge

7 wks / beckershospitalreview / Giles Bruce

Which AI companies health systems are betting on

7 wks / beckershospitalreview / Naomi Diaz

OpenEvidence launches hands-free voice AI feature, expands hospital footprint with Cedars-Sinai tie-up

7 wks / fiercehealthcare

Unintended consequences of legacy oversight in digital medicine

7 wks / nature / Jochen K. Lennerz

A workflow utilizing general-purpose large language models for efficient structuring and data mining of bone scintigraphy narratives

7 wks / nature

FDA approves early warning system for sepsis

1 month / medicalxpress

FDA clears 1st AI sepsis monitoring tool

1 month / beckershospitalreview / Giles Bruce

BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...

AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.

#pharmaceuticals #drugpricing #biotech #drugdevelopment #fda #oncology #healthcarefinance #cancerresearch

FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer Drug

1 month / medcitynews / Frank Vinluan

BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

1 month / endpoints / Ayisha Sharma

Positive VOLGA Phase III Results for Imfinzi Plus Neoadjuvant EV in MIBC

oncodaily - On May 14, 2026, AstraZeneca announced positive high-level results from a planned interim analysis of the Phase III VOLGA trial, evaluating perioperative Imfinzi with or without Imjudo in combination with […]

AI Summary: Phase III VOLGA trial results reveal that combining durvalumab (Imfinzi) with neoadjuvant enfortumab vedotin improved survival outcomes in muscle‑invasive bladder cancer. Investigators and industry voices highlight potential practice-changing implications for perioperative therapy, while stakeholders weigh regulatory filings and integration into treatment guidelines. Clinicians will want full datasets and toxicity details.